Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Global CAR T Therapy Trial Shows High Rates of Durable Remission for Non-Hodgkin’s Lymphoma: Additional data shows remissions past two years among patients treated in earlier pilot study.
Read moreCancer Immunotherapy Research
20 years of Penn Medicine's "ImmunoRevolution" that has created personalized immunotherapy treatments to reprogram the immune system to recognize and kill cancer cells.
Read moreDr. Bruce Levine Appointed as Deputy Director of Technology Innovation at CCI
New role to coordinate the assessment and integration of new technologies into the continuum of new cellular therapies at the Center for Cellular Immunotherapies (CCI).
Read moreFDA Approves Personalized Cellular Therapy for Advanced Leukemia
Landmark decision for the field of cancer immunotherapy for first therapy based on gene transfer approved by the FDA.
Read morePilot Study Tests CAR T-Cell Immunotherapy in Glioblastomas
Science Translational Medicine reports results of phase 1 safety study of autologous CAR T cells targeted to EGFR variant III in glioblastoma patients.
Read moreFDA Approval Recommendation for CAR T-Cell Therapy
FDA advisory committee unanimously approves first personalized cellular therapy developed at Penn for pediatric and young adult leukemia.
Read more
